Clinical trial · Interventional
Vaccine Therapy in Treating Patients Who Have Received First-Line Therapy for Hodgkin's Lymphoma
KGEL Vaccine After Initial Therapy of Hodgkin's Lymphoma
NCT00478062CI-TRIAL-00031851terminatedPhase 1 / Phase 2Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Poor accrual
Summary
Brief summary (as posted)
RATIONALE: Vaccines made from a tumor antigen may help the body build an effective immune response to kill tumor cells. PURPOSE: This phase I/II trial is studying the side effects and how well vaccine therapy works in treating patients who have received first-line therapy for Hodgkin's lymphoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| adjuvant therapy | Procedure | — | UNRESOLVED |
| Hodgkin's antigens-GM-CSF-expressing cell vaccine | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Cell vaccine after initial therapy for Hodgkin lymphoma
- description
- Hodgkin's antigens-GM-CSF-expressing cell vaccine after initial therapy.
- interventionNames
- Biological: Hodgkin's antigens-GM-CSF-expressing cell vaccine
- Procedure: adjuvant therapy
Primary outcomes (4)
- measure
- Immunologic Response
- timeFrame
- 9 months
- measure
- Durability of Immunologic Response
- timeFrame
- 2 years
- measure
- Utility of Epstein-Barr Virus Reporter System for Monitoring Cellular Vaccine Responses
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 120 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Diagnosis of classic Hodgkin's lymphoma * Must have completed first-line therapy without evidence of disease progression PATIENT CHARACTERISTICS: * HIV negative PRIOR CONCURRENT THERAPY: * See Disease Characteristics * No more than 6 months since prior chemotherapy or radiotherapy
References
Publications (0)
Data not yet available
No reference posted for this study.